NCT07929051
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Occurrence of treatment-emergent adverse events ( AEs) during the on-treatment period.
Timeframe: Up to 36 months
Secondary (1)
Obrixtamig treatment duration from the first administration in parent trial until the last administration in rollover trial.
Arms and interventions
Rollover armExperimental
Patients who have previously received treatment with obrixtamig in another Boehringer Ingelheim-sponsored clinical trial (referred to as the 'parent trial') will be enrolled in this rollover study. Treatment schedule and doses in the parent study will be continued in the rollover study.
Biologicals: Obrixtamig, Ezabenlimab, Atezolizumab, Tocilizumab
Drugs: Topotecan
Sites
15 sites in 6 countries
France 5, Germany 3, Japan 2, Poland 2, Spain 2, Belgium 1